Irinotecan
Myelodysplastic Syndrome With Excess Blasts-1
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Myelodysplastic Syndrome With Excess Blasts-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
METHOTREXATE Fred Hutchinson Cancer Center | Phase 2 | B |
TACROLIMUS Fred Hutchinson Cancer Center | Phase 2 | B |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 17 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →